Abstract: Multiple groups of nuclear fuel storage containers can be put into the nuclear fuel transport container provided by the present application as a whole to realize the overall transportation of the multiple groups of storage containers; the transport container has a cubic structure in appearance, which can fully utilize the transportation space and improve the transportation efficiency; an outer side of the transport container is provided with an anti-penetration structure, which can effectively alleviate the collision and penetration damage caused by transportation and hoisting accident, and ensure that the nuclear fuel element can be safely enclosed after the accident; heat insulation material is provided between inner and outer steel plates of the transport container, which can effectively protect the internal storage container and the loaded nuclear fuel element under fire condition, and the heat insulation material also has a function of drop buffer.

Abstract: Malaria still afflicts about half of the world population causing more than 400,000 deaths, mostly children. The options for malaria therapy are increasingly becoming limited because of widespread drug resistance. Furthermore, drugs for prophylaxis are suboptimal. This disclosure reports the identification of type II protein kinase inhibitor compounds which have never been explored as antimalarial agents and which now have been discovered to possess therapeutic and prophylactic properties against malaria.

Abstract: This disclosure describes methods of predicting the response of a patient with ovarian cancer to platinum-based chemotherapy and/or treatment with bevacizumab using clinical and molecular tumor characteristics in patients, methods of treating patients with ovarian cancer, and kits for performing all or part of the methods described herein. This disclosure also describes methods that include determining a prediction of an outcome for a patient having ovarian cancer based on one or more signatures and patient test data comprising clinical data, gene expression data, or both.

Abstract: Provide is a friction pair device comprising a friction pair stationary member, a plurality of micro channels, a Tesla valve structure, and a stress application device. The friction pair stationary member includes a friction pair static surface, which friction pair static surface is provided with a dynamic pressure groove. The dynamic pressure groove includes a dynamic pressure groove bottom. A surface of the dynamic pressure groove bottom is provided with micro-nano scale gaps. A super-lubricant is injected into the gaps to form a super-lubricant layer, allowing liquid medium molecules of a liquid-film to move freely along the dynamic pressure groove bottom. A slip velocity of the liquid medium molecules approaches a moving velocity of a friction pair dynamic surface, a slip length of the liquid medium molecules approaches positive infinity, and a super slip surface is formed on the dynamic pressure groove bottom.

Abstract: A multi-layer adhering label comprising a removable retail label having a first adhesive on its back side and a consumer label having a front surface capable of being written on with a writing instrument and an area for writing with the writing instrument and having a second adhesive on its back side. The back of the retail label is adhered to, and removable from, the front of the consumer label. The retail label covers at least a portion of the consumer label, carries the consumer label, and is removable from the consumer label. The area for writing of the front of the consumer label side can be written on with permanent marker (e.g., SHARPIE brand) and permanent marker writing can be removed from the front of the consumer label with a solvent.

Abstract: Systems, devices, and techniques are configured to determine associations between different genes, gene signatures, and gene ecosystems. In one example, a system includes processing circuitry configured to receive, from a data repository configured to store molecular abundance values for a plurality of samples, one or more matrices comprising at least one molecular abundance value for each sample of the plurality of samples, generate a first correlation matrix by performing a first statistical correlation operation between every pair of columns within the one or more matrices, generate a second correlation matrix by at least performing a second statistical correlation operation between every pair of columns within the first correlation matrix, determine, based on the second correlation matrix, a metric indicative of one or more gene ecosystems for one or more tissue types of at least one sample of the plurality of samples, and output, for display, the metric indicative of the one or more gene ecosystems.

Abstract: Multiple groups of nuclear fuel storage containers can be put into the nuclear fuel transport container provided by the present application as a whole to realize the overall transportation of the multiple groups of storage containers; the transport container has a cubic structure in appearance, which can fully utilize the transportation space and improve the transportation efficiency; an outer side of the transport container is provided with an anti-penetration structure, which can effectively alleviate the collision and penetration damage caused by transportation and hoisting accident, and ensure that the nuclear fuel element can be safely enclosed after the accident; heat insulation material is provided between inner and outer steel plates of the transport container, which can effectively protect the internal storage container and the loaded nuclear fuel element under fire condition, and the heat insulation material also has a function of drop buffer.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the disclosed compounds or compositions for treating and/or preventing diseases (e.g., inflammatory diseases, neurological diseases (e.g., Alzheimer's disease), infectious diseases (e.g., viral infections (e.g., infections caused by viral human hepatitis (e.g., hepatitis B), a flaviviridae family virus (e.g., a flavivims (e.g., Zika virus)))), and proliferative diseases (e.g., cancer (e.g., lung cancer, prostate cancer, skin cancer, thyroid cancer, pancreatic cancer, colorectal cancer, liver cancer, leukemia, or lymphoma)) in a subject. Provided are methods of inhibiting a protein kinase (e.g., MAP2K (e.g., MKK7)) in a subject. Also provided are methods of inhibiting MKK7 in a subject in need thereof.

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).

Abstract: The present disclosure discloses a steel strip coiling temperature control method, a steel strip coiling temperature control device and a steel strip processing system, which relate to the technical field of steel strip production. The method comprises: seeking a corresponding speed compensation coefficient according to a target thickness of the steel strip and a target temperature parameter; seeking a corresponding speed gain coefficient from a second correspondence table according to a steel strip speed; correcting the steel strip speed based on the speed compensation coefficient and the speed gain coefficient to obtain a corrected steel strip speed; and adjusting a cooling efficiency of a laminar flow cooling apparatus according to the corrected steel strip speed.

Abstract: The present application provides bifunctional compounds of Formula X or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.

Abstract: Disclosed is an integrated projection and illumination device. The integrated projection and illumination device includes a lamp housing, a mounting assembly, an illumination assembly and a projection assembly; and the mounting assembly includes a mounting disc, a mounting ring and clamping blocks, elastic members being arranged between the clamping blocks and the mounting ring, the mounting disc being provided with top surface connectors and an outer limiting edge, the outer limiting edge being capable of being clamped on the clamping blocks protruding out of the inner wall of the mounting ring, the mounting disc being further provided with pressing blocks, and the pressing blocks rotating along with the mounting disc and being capable of making contact with the clamping blocks and pressing the clamping blocks into the mounting ring during rotation. The present disclosure can be used for illumination and projection, and further features convenient dismounting and mounting.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the disclosed compounds or compositions for treating and/or preventing diseases (e.g., inflammatory diseases, neurological diseases (e.g., Alzheimer's disease), infectious diseases (e.g., viral infections (e.g., infections caused by viral human hepatitis (e.g., hepatitis B), a flaviviridae family virus (e.g., a flavivims (e.g., Zika virus)))), and proliferative diseases (e.g., cancer (e.g., lung cancer, prostate cancer, skin cancer, thyroid cancer, pancreatic cancer, colorectal cancer, liver cancer, leukemia, or lymphoma)) in a subject. Provided are methods of inhibiting a protein kinase (e.g., MAP2K (e.g., MKK7)) in a subject. Also provided are methods of inhibiting MKK7 in a subject in need thereof.

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).

Abstract: Disclosed is an integrated projection and illumination device. The integrated projection and illumination device includes a lamp housing, a mounting assembly, an illumination assembly and a projection assembly; and the mounting assembly includes a mounting disc, a mounting ring and clamping blocks, elastic members being arranged between the clamping blocks and the mounting ring, the mounting disc being provided with top surface connectors and an outer limiting edge, the outer limiting edge being capable of being clamped on the clamping blocks protruding out of the inner wall of the mounting ring, the mounting disc being further provided with pressing blocks, and the pressing blocks rotating along with the mounting disc and being capable of making contact with the clamping blocks and pressing the clamping blocks into the mounting ring during rotation. The present disclosure can be used for illumination and projection, and further features convenient dismounting and mounting.

Abstract: Provided herein are methods of treating diseases (e.g., proliferative disease (e.g., cancer (e.g., breast cancer, colon cancer, testicular cancer, CNS cancer, stomach cancer, lymphoma (e.g., B-cell lymphoma (e.g., lymphoplasmacytic lymphoma (e.g., IgM secreting lymphoplasmacytic lymphoma (i.e., Waldenstrom's Macroglobulinemia), non-IgM secreting lymphoplasmacytic lymphoma)), diffuse large B-cell lymphoma (e.g., activated B-cell-like (ABC)-DLBCL, germinal center B-cell-like (GBC)-DLBCL), follicular lymphoma, marginal zone B-cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma), and leukemia (e.g., chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, myelogenous leukemia (e.g., chronic myelogenous leukemia, acute myelogenous leukemia))))) comprising administering to the subject in need thereof a therapeutically effective amount of Compound (I). Further provided are methods for treating disease resistant to treatment with BTK inhibitors (e.g., ibmtinib).

Abstract: Disclosed are bispecific compounds (degraders) that target ERK5 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat cancer and inflammatory diseases.

Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a kinase (e.g., HCK, BTK) to induce degradation of the kinase (e.g., HCK, BTK). Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., non-Hodgkin's lymphoma, Burkitt's lymphoma, Waldenstrom macroglobulinemia, MYD88-mutated Waldenstrom macroglobulinemia, activated B-cell diffuse large B-cell lymphoma, leukemia)), inflammatory disease, or other diseases associated with MYD88 mutations). Provided also are methods of inducing the degradation of a kinase (e.g., HCK, BTK) in a cell in a biological sample or subject by administering the bifunctional compound or composition described herein.